Transient receptor potential vanilloid subtype 1 depletion mediates mechanical allodynia through cellular signal alterations in small-fiber neuropathy

Chin-Hong Chang\textsuperscript{a}, Ying-Shuang Chang\textsuperscript{b}, Yu-Lin Hsieh\textsuperscript{b,c,d,*}

Abstract

Transient receptor potential vanilloid subtype 1 (TRPV1) is a polymodal nociceptor that monitors noxious thermal sensations. Few studies have addressed the role of TRPV1 in mechanical allodynia in small-fiber neuropathy (SFN) caused by sensory nerve damage. Accordingly, this article reviews the putative mechanisms of TRPV1 depletion that mediates mechanical allodynia in SFN. The intraepidermal nerve fibers (IENFs) degeneration and sensory neuronal injury are the primary characteristics of SFN. Intraepidermal nerve fibers are mainly C-polymodal nociceptors and A\textsubscript{d}-fibers, which mediated allodynic pain after neuronal sensitization. TRPV1 depletion by highly potent neurotoxins induces the upregulation of activating transcription factor 3 and IENFs degeneration which mimics SFN. TRPV1 is predominately expressed by the peptidergic than nonpeptidergic nociceptors, and these neurochemical discrepancies provided the basis of the distinct pathways of thermal analgesia and mechanical allodynia. The depletion of peptidergic nociceptors and their IENFs cause thermal analgesia and sensitized nonpeptidergic nociceptors respond to mechanical allodynia. These distinct pathways of noxious stimuli suggested determined by the neurochemical-dependent neurotrophin cognate receptors such as TrkA and Ret receptors. The neurogenic inflammation after TRPV1 depletion also sensitized Ret receptors which results in mechanical allodynia. The activation of spinal TRPV1(+) neurons may contribute to mechanical allodynia. Also, an imbalance in adenosinergic analgesic signaling in sensory neurons such as the downregulation of prostatic acid phosphatase and adenosine A\textsubscript{1} receptors, which colocalized with TRPV1 as a membrane microdomain also correlated with the development of mechanical allodynia. Collectively, TRPV1 depletion–induced mechanical allodynia involves a complicated cascade of cellular signaling alterations.

Keywords: P2X3, TrkA receptor, Ret receptor, Prostatic acid phosphatase, Adenosine A\textsubscript{1} receptor, Calcitonin gene–related protein, Activating transcription factor 3

1. Introduction

The transient receptor potential vanilloid subtype 1 (TRPV1), also known as capsaicin receptor, is encoded in humans by the trpv1 gene. The TRP family of receptors (including several subtypes)\textsuperscript{61} and their physiological function are well established in the literature.\textsuperscript{16,17,61} TRPV1 was first cloned by Caterina et al.\textsuperscript{17} and has been a well-known receptor. Transient receptor potential vanilloid subtype 1 is a nonselective ion channel and a polymodal nociceptor\textsuperscript{16,153} used to detect and regulate body temperature as well as respond to heat and pain signals.\textsuperscript{128} Transient receptor potential vanilloid subtype 1 acts as a thermoreceptor.\textsuperscript{16} Transient receptor potential vanilloid subtype 1 is expressed by small-diameter nociceptors, and TRPV1 depletion has specifically been reported to result in thermal analgesia.\textsuperscript{16,61} The molecular mechanisms of TRPV1-mediated thermal analgesia are related to the cytotoxicity induced by increased calcium permeability and the influx of Ca\textsuperscript{2+} into TRPV1(+) nociceptors.\textsuperscript{39,42} Patients with small-fiber neuropathy (SFN) experience various nociceptive sensations\textsuperscript{64,160} such as reduced noxious thermal sensation (thermal analgesia) and mechanical

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

\textsuperscript{a} Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan, \textsuperscript{b} Department of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, \textsuperscript{c} School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, \textsuperscript{d} Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

*Corresponding author. Address: School of Post-Baccalaureate Medicine, College of Medicine, Kaohsiung Medical University, 100 Shih-Chuan 1st Rd, Kaohsiung 80708, Taiwan. Tel.: 886-7-3121101. E-mail address: ylhsieh@kmu.edu.tw (Y.-L. Hsieh).

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The International Association for the Study of Pain. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PR9 6 (2021) e922

http://dx.doi.org/10.1097/PR9.0000000000000922

www.painreportsonline.com
1.1. Roles of transient receptor potential vanilloid subtype 1 in small-fiber neuropathy models

The skin is innervated by intraepidermal nerve fibers (IENFs) which respond to external stimuli, and skin denervation is a common clinicopathological manifestation of SFN. Neuroanatomically, these IENFs are mainly C-polymodal nociceptors and Aδ-fibers, which mediated allodynic pain confirmed by neuropharmacological blockade. However, studies using animal neuropharmacological blockade, evoked potentials recording, and genetic expression. Particularly, the C-polymodal nociceptors are further categorized as mechano-heatorresponsive units and mechano-insensitive units (CMIs) according to the different electrical thresholds. Past studies suggested CMIs became sensitized by tissue damage (i.e., skin denervation), nerve growth factor (NGF), and capsaicin administration. Therefore, the neuropathology of skin denervation provided a basis for evaluating the alteration of pain perception. The combination of skin biopsy and protein gene product 9.5-immunohistochemistry is a useful clinical diagnostic tool for assessing skin denervation in patients with SFN. It has been reported to provide reliable diagnosis and progress prediction in SFN. This skin biopsy assessment has also been applied to various animal models of SFN, particularly in cases of degeneration of TRPV1(+) IENFs, which may sensitize their neuronal soma in the dorsal root ganglia (DRG). The benefit of these animal models of SFN is that they allow the simultaneous assessment of skin denervation and the degree of neuronal soma injury. For example, the different pathophysiological responses of IENFs and TRPV1 (+) neuronal soma may have paradoxical neurophysiological outcomes. However, studies using animal models of diabetes-induced SFN have not addressed the factors affecting the development of neuropathic pain by sensitized and/or irritated large sensory nerves and identifying these factors may delineate the role of TRPV1 in the development of mechanical allodynia, which has a high incidence among patients with diabetes-induced SFN.

Studies have used highly selective neurotoxins to TRPV1 such as capsaicin and systemic resiniferatoxin (RTX) treatment to induce skin denervation, confirming the role of thermal transmission in SFN. Genetic knockout of TRPV1 has resulted in similar outcomes. In another study, highly selective and highly potent neurotoxins depleted TRPV1, inducing pure SFN that spared large sensory nerves. Furthermore, Pan et al. and our research group demonstrated that TRPV1(+) nociceptors had a paradoxical effect on thermal and mechanical sensitivity after systemic neurotoxicity was induced in the naive rodent. The genetic deletion of TRPV1 also reversed mechanical allodynia that was induced in a neurogenic inflammation model. Collectively, it is believed the role of TRPV1 in SFN may involve several neuronal and immune responses, suggesting that alteration of TRPV1 pathophysiology is a critical factor.

1.2. Transient receptor potential vanilloid subtype 1-expressing peptidergic vs nonpeptidergic nociceptors

Small-diameter nociceptors are categorized into 2 types according to their neurotrophic characteristics: peptidergic and nonpeptidergic nociceptors. TRPV1 is predominantly expressed by peptidergic nociceptors and less commonly coexpressed by nonpeptidergic nociceptors. The peripheral processes of these peptidergic and nonpeptidergic nociceptors terminate on skin response to different types of noxious stimuli. The colocalized ratios of TRPV1 and peptidergic(+) nociceptors are correlated with different neurophysiological outcomes. For example, approximately 20%-50% of calcitonin gene–related peptide (CGRP) (+) nociceptors coexpress TRPV1 in the DRG of rodents, and the reinnervation of CGRP (+) IENFs reverses thermal analgesia after TRPV1 depletion, which may do to TRPV1 depletion after the expression of neuronal phenotypes and neurophysiological functions. By contrast, denervation of substance P (+) IENFs reportedly results in a loss of thermal response ability because of the low density of IENFs and high colocalization (40%-60%) with TRPV1. These peptidergic neuronal soma exhibit the same pathology as their peripheral IENFs. In addition to thermal transmission, the depletion of these peptidergic neurons after TRPV1 depletion improved periodontitis, arthritis, and orthodontic force–derived mechanical irritation by altered inflammatory response. Collectively, the elimination of peptidergic neurons after TRPV1 depletion may alter systemic neurophysiological function which involved inflammatory responses.

Pathological evidence indicates that the ratio of TRPV1 colocalized with different phenotypic nociceptors is a critical factor for different neuropathic behaviors. For example, TRPV1 has limited expression by nonpeptidergic (also called purinergic) P2X3 nociceptors, and specifically, P2X3(+) nociceptors sensitized by highly potent neurotoxins respond to mechanical allodynia because of the burst release of adenosine triphosphate (ATP) from denervated skin and injured DRG tissues. The other desensitized nonpeptidergic nociceptors that coexpress with TRPV1 also exhibit similar neuropathic behaviors. For example, the downregulation of the prostatic acid phosphatase (PAP), which is highly coexpressed with P2X3(+) nociceptors (up to 87%) and approximately 50% coexpressed with TRPV1, correlates with the development of mechanical allodynia. In addition to TRPV1 (+) neuronal soma and their peripheral IENFs correlated to the noxious stimulation, pre-synaptic TRPV1 (+) central terminals on the spinal cord suggested modulated the postsynaptic current activities. This neurophysiological modulation by TRPV1 is further confirmed by c-fos activation on postsynaptic spinal interneurons after TRPV1 activation at the periphery. The expression of TRPV1 (+) central terminals and interneurons showed their neurophysiological plasticity that suggested commonly contribute to painful sensation, which was regulated by the pathways from the ventromedial medulla and thalamus in brainstem and diencephalon, respectively, to spinal TRPV1 (+) interneurons. Particularly, TRPV1 activation expressed by spinal GABAergic interneurons mediated mechanical allodynia by the disinhibition of long-term depression in the spinothalamic tract. Collectively, topographical TRPV1 expression played an important role in plastic neuronal activity for pain transmission.

Notably, the neurophysiological functions of small-diameter nociceptors depend on the regulation of neurotrophic signals; the reinnervation of CGRP (+) peptidergic IENFs normalizes the thermal noxious sensation that underlies the activation of NGF-TrkA signaling. TrkA is the high-affinity receptor of NGF that regulates the neurophysiological functions of peptidergic nociceptors. NGF-TrkA signaling also regulates the neurophysiological functions of nonpeptidergic PAP (+) nociceptors through high PAP/TrkA colocalization ratios (approximately 70%). However, 2 studies have reported that the activation...
of NGF-TrkA signaling has no effect on TRPV1 recovery, despite TRPV1/TrkA colocalization ratios of approximately 30%-50%. Furthermore, NGF has been found to normalize neuropathic manifestations through distinct neurotrophin receptor–dependent pathways. For example, NGF has paradoxical effects, such as upregulation of TrkA, the peptidergic nociceptor–dependent neurotrophin receptor, and downregulation of the nonpeptidergic nociceptor–dependent Ret receptor. Evidence from pharmacological interventions indicates that the activation of Ret receptors mediates both thermal and mechanical noxious sensations and that TrkA receptors have no effect on mechanosensation. Notably, the expression of different neurotrophin cognate receptors such as activating transcription factor 3 (ATF3) is associated with intranuclear signaling, suggesting that these injury-dependent molecules expressed by different neurotrophin cognate receptors are critical factors in the development of neuropathic pain.

The different phenotypes of small-diameter nociceptors have a wide spectrum of profiles colocalized with TRPV1 that exhibit distinct neurophysiological functions, such as the induction of both thermal analgesia and mechanical allodynia after TRPV1 depletion, which is mediated by 2 distinct noxious pathways regulated by specific neurotrophins and their cognate receptors.

1.3. Correlation of neuronal soma injury after transient receptor potential vanilloid subtype 1 depletion with neurotrophic receptor expression and pain development

Transient receptor potential vanilloid subtype 1 depletion and the degeneration of IENFs cause a cascade of responses in the neuronal soma. For example, ATF3 is a member of the ATF/CREB transcription factor superfamily. Activating transcription factor 3 dimerizes with c-Jun, which responds to neuronal irritation and outgrowth on different types of neurons. In addition, ATF3 acts as an effector molecule in small-diameter nociceptors that respond to maladaptive behaviors of neuropathic pain. Recently, comprehensive studies have demonstrated increased ATF3 upregulation in DRG neurons following various nerve injuries and exposure to noxious stimuli. ATF3 upregulation by small-diameter nociceptors is specific and differential, and the phenotypic profiles of ATF3 provide molecular explanations for manifested behaviors. For example, ATF3 has been reported to be preferentially upregulated by small-diameter nociceptors, suggesting the susceptibility and topographical relationship of ATF3 to neuropathic pain. Although ATF3 is preferentially expressed by small-diameter nociceptors after TRPV1 depletion, this ATF3 upregulation is distinct. For example, ATF3 was reported to be predominantly expressed by nonpeptidergic nociceptors such as P2X3 (+) and PAP (+) nociceptors rather than by CGRP (+) peptidergic nociceptors. In addition, ATF3 upregulation was linked to skin denervation and phenotypic changes in nonpeptidergic nociceptors. Another study reported opposite results; ATF3 was reported to be predominantly expressed by peptidergic CGRP (+) nociceptors. Transient receptor potential vanilloid subtype 1 depletion by neurotoxicity is a comprehensive neuropathological effect of the skin denervation response to transcription factors in neuronal soma, suggesting that ATF3 activity as a pain indicator directly reflects nerve injury and that expression by nonpeptidergic nociceptors is necessary for pain development. However, ATF3 has also been documented to act as a simplified marker for injury rather than a pain marker. Furthermore, extracellular signaling is coordinated with intracellular ATF3 responses. The enhancement of extracellular purinergic signaling occurs in parallel with TRPV1 depletion and the burst release of ATP from injured DRG tissues. Notably, extracellular ATP also acts as a gliotransmitter to mediate glial activation in pain development through communication with microglia and astrocytes and neuronal interactions, which are also factors affecting pain development. Thus, the burst release of ATP from injured tissues is also associated with the neuroinflammation that mediates neuropathic manifestations.

Intracellular signal cascades of ATF3 involve activation of the c-Jun/c-Jun N-terminal kinase (JNK) signal pathway during axonal transportation activity, which may mediate neuronal stress signals. In addition to ATF3, activating transcription factor 2 (ATF2) acts as a responding molecule in pathological manifestations. It is activated by JNK in diabetic neuropathy. Although few studies have reported an association between ATF2 expression and TRPV1 expression, ATF2 is a potential upstream molecule that regulates TRPV1-mediated inflammatory pain.

1.4. Transient receptor potential vanilloid subtype 1 depletion results in neuroinflammatory pain

Skin denervation and neuronal soma injury are typical neuropathological characteristics of SFN. They result in neurogenic inflammation, also referred to as neuroinflammation, which is associated with neuropathic behavior. Tumor necrosis factor-α (TNFα) is a major pleiotropic cytokine that mediates neuroinflammation through activation of the TNF receptor 1 (TNFR1) ligand receptor. TNFα and TRPV1 are considered 2 critical mediators of inflammatory pain, suggesting that functional TRPV1 is required for the development of inflammatory pain mediated by TNFα. Blocking TNFα/TNFR1 signaling is a new therapeutic strategy for inflammatory diseases and is particularly effective in alleviating injury-induced neuropathic pain. Notably, one study reported that Ret receptor–mediated nociceptive behavior was reversed by TNFR1 loss, suggesting that the interaction of TNFα with nociceptors rather than with TRPV1 is a more critical factor for the development of neuropathic behavior. However, colocalized studies of TNFR1 (+)/TRPV1 (+) neurons have demonstrated that TNFR1 may play a silent role in neuropathic behavior after TRPV1 depletion by the highly potent neurotoxin RTX. Instead, TNFα sensitizes Ret (+) neurons, which mediate mechanical allodynia after TRPV1 depletion by neurotoxins; for example, RTX induces a burst of TNFα that further sensitizes and upregulates Ret (+) neurons in addition to TRPV1. Moreover, TNFα-deficient mice have been found to exhibit fewer nonpeptidergic Ret (+) neurons, suggesting that Ret/TNFα signaling is required in neurotoxin-induced neuropathy, which is mediated by a TRPV1-independent pathway. One study also demonstrated that TNF receptor 2 (TNFR2), another receptor of TNFα, is a major responding effector that mediates TRPV1-dependent inflammatory pain. The collective evidence indicates that TNFα initiates upstream signaling and that, in concert with its cognate receptors, has a broad spectrum of roles in the development of neuropathic pain.

Interleukin-6 (IL-6) and interleukin-1β (IL-1β) belong to another category of cytokines involved in neuroinflammation. Reduction of IL-6 and IL-1β may relieve neuropathic pain through attenuated TRPV1 expression. In several neuropathic models, the parallel expression of TRPV1 and cytokines was correlated with pain development. These findings suggest...
that proinflammatory cytokine–mediated pain sensation requires TRPV1 activation.

TNFα neutralization is currently used for clinical treatment of autoimmune diseases,\(^{85}\) and TNFα-inhibitory drugs are also used to inhibit glial cell activation in neuropathic pain treatment.\(^{100}\) Neuroinflammation induces neuropathic behavior through TNFα-mediated activation of glial cells.\(^{7,133}\) TNFα sensitizes Ret (+) neurons, which mediate neuropathic behavior through an alternative pathway. Generally, glial cell line–derived neurotrophic factor (GDNF) is used as an analgesic agent that acts as a ligand to the Ret receptor, regulating its function and morphology.\(^{43,98,133}\) An NGF inducer, 4-methylcatechol (4-MC),\(^{3,121}\) has been demonstrated to suppress neuropathic behavior\(^{52}\) and enhance neuroregeneration.\(^{51,54,63}\) However, NGF also induced neurogenic inflammation followed by mechanical allodynia, which mediated by unsilencing nicotinic acetylcholine receptor subunit α-3 (CHRNA3) (+) peptidergic nociceptors\(^{124}\) and activated previous silent nociceptors.\(^{44}\) Noteworthy, the elimination of CHRNA3 (+) nociceptor after TRPV1 depletion\(^{72}\) sparing NGF-induced neurogenic inflammation.

Studies have also shown that 4-MC induces GDNF synthesis\(^{54}\) and normalizes the upregulation of Ret (+) neurons and neuropathic behavior.\(^{52}\) The normalization of TNFα and Ret receptors could be targeted in the development of a pharmacological intervention that could provide a new therapeutic direction in the treatment of SFN beyond glial cell activation. The signaling interactions between TNFα and Ret require further investigation.

1.5. Role of microdomains in transient receptor potential vanilloid subtype 1 signaling transduction

The cell membrane microdomain is a microstructure whose structural integrity is essential in functional physiology. The structural alteration of microdomains is correlated with neuronal pathogenesis, such as that of peripheral pathology,\(^{24,84,148}\) antagonizes hyperalgesia,\(^{27}\) and inhibits endocannabinoid-mediated analgesic systems.\(^{128}\) Microdomains have a complex composition of lipid derivatives\(^{132}\) and have received increasing attention for their relation to nociceptive modulation.\(^{18,37,82,86,132,136}\) Microdomains are also involved in the modulation of nociceptive development.\(^{96,132,150}\) Growing evidence suggests that TRPV1 is a microdomain component that modulates nociceptive transmission, particularly through interaction with nociceptive molecules.\(^{11,96,131,149}\) Microdomain signaling requires the hydrolysis of phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2],\(^{149}\) a process also involved in PAP-mediated antinociception through the prevention of TRPV1-sensitized noxious sensations.\(^{55,149}\) Molecular intervention between TRPV1 and PAP involves a PI (4,5) P2 signal. TRPV1 depletion is associated with PAP downregulation, which results in higher PI (4,5) P2 availability, which acts as an agonist of TRPV1 to modulate TRPV1 activity.\(^{4,123}\) PI (4,5) P2 metabolism is also involved in inhibiting the mechanosensitive receptors modulated by TRPV1 activation.\(^{3}\) Furthermore, PAP downregulation is associated with an imbalance in analgesic adenosinergic signaling.\(^{65,162}\) For example, adenosine receptors mediate cellular analgesia through adenosine ligand–activated adenosine receptors.\(^{9,138,164}\) In particular, adenosine A1 receptor (A1R) activation plays a key role in SFN.\(^{56,167,166}\) Downregulation of PAP (+) neurons reduces their ectonucleotidase activity, which in turn reduces the hydrolysis of AMP to adenosine, resulting in the inhibition of cellular adenosine.\(^{56}\)

One study found that microdomain disruption by cholesterol depletion with methyl-β-cyclodextrin (MBC) preserves PAP-mediated antinociception through PI (4,5) P2 hydrolysis,\(^{90}\) indicating that TRPV1 and PAP are located in cholesterol-rich microdomains. These findings suggest that intracellular signal alterations also contribute to pain modulation. However, another study demonstrated that TRPV1 depletion had paradoxical

![Image](image_url)

Figure 1. Mechanism of thermal analgesia and mechanical allodynia induced by transient receptor potential vanilloid subtype 1 (TRPV1) depletion in small-fiber neuropathy. TRPV1 receptors were depleted by highly selective neurotoxins such as resiniferatoxin (1) and induced thermal analgesia and mechanical allodynia through 2 distinct pathways. The depletion of TrkA receptors, which were expressed by peptidergic calcitonin gene–related peptides and substance P (+) neurons (2), resulted in thermal analgesia (3). By contrast, nonpeptidergic TRPV1 (+) neurons upregulated activating transcription factor 3 (ATF3) expression, which reflected underlying injury of neuronal soma (4), resulting in a burst of TNFα (5). TNFα had no effect on TNFR1 because it was depleted as a result of its high degree of colocalization with TRPV1 (6) but sensitized Ret receptors (7), leading to the development of mechanical allodynia (8). TRPV1 colocalized with prostatic acid phosphatase and A1R within the same cell membrane microdomain. TRPV1 depletion caused an imbalance in analgesic adenosinergic signaling that induced the downregulation of prostatic acid phosphatase (9), which resulted in reduced hydrolysis of adenosine by AMP (10). This in turn reduced the capacity of A1R-mediated cellular allodynia (11). Structural disruption of microdomains by cholesterol depletion is associated with reduced PI (4,5) P2 hydrolysis (12), which leads to mechanical allodynia (13).
effects on nociceptive transmission; for example, TRPV1 depletion from microdomains induced neuropathic pain.\(^\text{65}\) Microdomains labelled by flotillins 1 (FLOT1) and flotillins 2 (FLOT2) as well as microdomains within sensory neurons have an abundance of FLOT1 and FLOT2. A1R also coexpresses with FLOT1 and FLOT2, and these FLOT1 (+) and FLOT2 (+) neurons are depleted after TRPV1 depletion associated with the development of mechanical allodynia.\(^\text{90}\) These findings suggest that microdomains containing cellular analgesic molecules on sensory neurons act as functional units for pain transmission.

In addition, microdomains contain nociceptive receptors such as P2X3,\(^\text{7,37,106,154}\) and P2X3 may act as the downstream molecule of PI (4,5) P2.\(^\text{102,155}\) Moreover, PI (4,5) P2 modulation of P2X3 may occur through autocrine signaling because of the high colocalization of PAP and P2X3 in DRG neurons.\(^\text{156}\) These collective findings indicate that TRPV1 depletion initiates a cascade of signaling alterations caused by the neuronal injury response to degeneration of peripheral IENFs after neurotoxin-induced SFN.

1.6. Clinical implications for pain management of lipid derivatives of microdomains

Most SFN studies have focused on investigating the responses and contributions of sensitized small-diameter nociceptors after those nociceptors suffer injury and irritation.\(^\text{19,50,111,117,142}\) Microdomains act as functional units of nociceptive transmission and could contribute to the development of new first-line pharmacotherapeutic treatments. Microdomains are composed of cholesterol, sphingomyelin, and gangliosides,\(^\text{122,123}\) and studies have demonstrated that the TRPV1 activity is affected by altered ganglioside synthesis\(^\text{132,137,150}\) and sphingomyelin inhibition.\(^\text{132,150}\) Sphingomyelin signaling modulates nociception through the activation of p75 neurotrophin receptors,\(^\text{73,74}\) and NGF regulates TrkA receptor activation through alteration of these lipid derivatives.\(^\text{89}\) In addition, some G protein–coupled receptors are intracellular components of microdomains and are involved in nociceptive development.\(^\text{104,107}\) The elimination of lipid metabolic constituents is a potential target for the pain management of lipid metabolism disorders related to microdomain–attributed peripheral neuropathy.\(^\text{34,89,116,116}\) Lipid derivatives in microdomains were demonstrated to be sensitive to drug-induced disruption of microdomains.\(^\text{38}\) Therefore, targeting the cytoplasm membranes surrounding microdomains could constitute a new therapeutic direction. Multiple doses of drugs may be required for the depletion of lipid derivatives because of the dynamic replenishment of cholesterol from intracellular stores.\(^\text{34}\)

2. Conclusions

Transient receptor potential vanilloid subtype 1 acts as a polymodal nociceptor that responds to different noxious stimuli. Commercial capsaicin dermal patch (Qutenza) with 8% (wt/wt) capsaicin has high efficacy for treatment SFN\(^\text{3,155}\) such as diabetic peripheral neuropathy. Local analgesia by a high concentration of capsaicin because of axonal degeneration by cytoskeleton disassembly and mitochondrial fission,\(^\text{21}\) which showed "defunctionalization" of nociceptor peripheral fibers including the transient loss of membrane potential, inability to axonal transport of neurotrophic factors, and reduction of IENFs.\(^\text{2}\) Noteworthy, administration routes determined the survival of TRPV1 (+) neuronal soma and nociceptive-related neuropeptides expression at different nervous tissues.\(^\text{6}\) It believed TRPV1 agonist administration through different routes had distinct effects on neurophysiological responses. This article reviews the role of TRPV1 in SFN. In particular, it discusses the depletion of TRPV1 by highly potent neurotoxins such as RTX, which induces a cascade of extracellular and intracellular signaling alterations caused by peripheral skin denervation and injury to central sensory neurons. Figure 1 summarizes the putative mechanisms of neuropathic manifestations induced by TRPV1 depletion.

Disclosures

The authors have no conflicts of interest to declare.

Acknowledgements

This research was funded by Ministry of Science and Technology (108-2320-B-037-028-MY3 and 109-2314-B-037-063) as well as Chi-Mei Medical Center and Kaohsiung Medical University Research Foundation (108CM-KMU-04), all of which are from Taiwan. The funding sponsor had no role in the conduct of the article preparation. The authors declare no conflict of interest.

Article history:
Received 4 December 2020
Received in revised form 22 January 2021
Accepted 22 February 2021
Available online 2 April 2021

References

[1] Abrams RMC, Pedowitz EJ, Simpson DM. A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. Expert Rev Neurother 2021. doi: 10.1080/14737175.2021.1874920 [Epub ahead of print].
[2] Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth 2011;107:490–502.
[3] Backonja M, Wallace MS, Blosny SK, Cutler BJ, Malan P Jr, Rauck R, Tobias J, Group N-CS. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 2008;7:1106–12.
[4] Bevan S, Quello T, Andersson DA. TRPV1. Handb Exp Pharmacol 2014;222:207–45.
[5] Bishnoi M, Bosgraaf CA, Abooj M, Zhong L, Premkumar LS. Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: role of transient receptor potential vanilloid 1 (TRPV1) and inflammatory mediators. Mol Pain 2011;7:52.
[6] Bishnoi M, Bosgraaf CA, Premkumar LS. Preservation of acute pain and sensitized function following intrathecal resveratrol-induced analgesia in rats. J Pain 2011;12:991–1003.
[7] Bleich D, Chen S, Zipser B, Sun D, Funk CD, Nadler JL. Resistance to type 1 diabetes induction in 12/loxoxgenase knockout mice. J Clin Invest 1999;103:1431–6.
[8] Borbiro I, Badheka D, Rohacs T. Activation of TRPV1 channels inhibits mechanosensitive Piezo channel activity by depleting membrane phosphoinositides. Sci Signal 2015;8:ra15.
[9] Borea PA, Gessi S, Menghi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiol Rev 2018;98:1591–625.
[10] Borouchchavan A, Gibbons CH. Utility of skin biopsy in management of small fiber neuropathy. Muscle Nerve 2013;48:877–82.
[11] Bottschuev S, van Diest SA, van Thiel IAM, Saia RS, Strik AS, Yu Z, Elferink RPO, Schuren FHJ, de Jonge WJ, van den Wijngaard RM. Miltefosine treatment reduces visceral hypersensitivity in a rat model for inflammatory bowel syndrome via multiple mechanisms. Sci Rep 2019;9:12590.
[12] Braz JM, Basbaum AI. Differential ATP3 expression in dorsal root ganglion neurons reveals the profile of primary afferents engaged by diverse noxious chemical stimuli. PAIN 2010;150:290–301.
[35] Giannoccaro MP, Donadio V, Incenci A, Piazza F, Cason E, Di Stasi V, Martineili P, Scaglione C, Capellan S, Treglia G, Liguori R. Skin biopsy and I-123 MIBG scintigraphy findings in idiopathic Parkinson’s disease and parkinsonism: a comparative study. Mov Disord 2015;30:986–9.

[36] Gibbons CH, Wang N, Freeman R. Capsaicin induces degeneration of cutaneous autonomic nerve fibers. Ann Neurol 2010;68:888–98.

[37] Gnanasekaran A, Sundaram M, van den Maagdenberg AM, Fabreotti E, Nisti A. Lipid rafts control P2X3 receptor distribution and function in trigeminal sensory neurons of a transgenic migraine mouse model. Mol Pain 2011;7:77.

[38] Gomide AB, Thorne CH, dos Santos GA, Ferreira GA, Faca VM, Rego EM, Greene LJ, Stabeli RG, Ciangappi P, Itri R. Disrupting membrane raft components by alkyphospholipids. Biochim Biophys Acta 2013;1828:1384–9.

[39] Goswami C, Dregger M, Jahnel R, Bogen O, Gillen C, Huclo F. Identification and characterization of a Ca2+-sensitive interaction of the vanilloid receptor TRPV1 with tubulin. J Neurochem 2004;91:1092–103.

[40] Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homoeodomains. Gene 2001;273:1–11.

[41] Hai T, Woldorf CC, Chang YS. ATP3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? Gene Exp 2010;15:1–11.

[42] Han P, McDonald HA, Bianchi BR, Kouhen RE, Vos MH, Janvis MF, Faltynek CR, Moreland RB. Capsaicin causes protein synthesis inhibition and microtubule disassembly through TRPV1 activities both on the plasma membrane and intracellular membranes. Biochem Pharmacol 2007;73:1635–45.

[43] Heccon KM, Murtie JC, Alger K, Calcutt NA, Corfas G. Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFP/PLA2 receptor signaling. Proc Natl Acad Sci USA 2014;111:2325–30.

[44] Hirth M, Rukwied R, Gromann A, Turnquist B, Weinkauf B, Franke K, Abrecht P, Rice F, Hagglow F, Ringkamp M, Engelhardt M, Schultz C, Schmetz M, Obreja O. Nerve growth factor induces sensitization of nociceptors without evidence for increased intraneural fiber density. Pain 2013;154:2500–11.

[45] Hofmann L, Hose D, Griesshammer A, Blum R, Doring F, Dib-Hajj S, Waxman S, Sommer C, Wichtermyer E, Uceyler N. Characterization of small fiber pathology in a mouse model of Fabry disease. Elife 2018;7:e39300. doi: 10.7554/eLife.39300.

[46] Hohmann AG, Neely MH, Pina J, Nackley AG. Neonatal chronic hind paw inflammation alters sensitization to intradermal capsaicin in adult rats: a behavioral and immunocytochemical study. J Pain 2005;6:798–808.

[47] Horvath A, Borbely E, Bolcskei K, Szentes N, Kiss T, Belak M, Rauch T, Boldizsar F, Helyes Z, Botz B. Regulatory role of capsacin-sensitive sensory nerves in the proteoglycan-induced autoimmune arthritis model of the mouse. J Neuroinflammation 2015;12:355.

[48] Hsiao TH, Fu YS, Ho WY, Chen TH, Hsieh YL. Promotion of thermal analgesia and neuropeptidergic skin reinnervation by 4-methylcatechol in resiniferatoxin-induced neuropathy. J Peripher Nerv Syst 2011;16:S21.

[49] Hsieh YL, Lin CL, Chiang H, Fu YS, Lue JH, Hsieh ST. Role of potential ankyrin 1 and vanilloid 1 activity potentiates glutamatergic input to trigeminal sensory neurons of a transgenic migraine mouse model. Mol Pain 2015;11:1269–81.

[50] Huang Y, Chen SR, Chen H, Pan HL. Endogenous transient receptor potential ankyrin 1 and vanilloid 1 activity potentiates glutamatergic input to trigeminal sensory neurons of a transgenic migraine mouse model. Mol Pain 2015;11:1269–81.
to spinal lamina I neurons in inflammatory pain. J Neurochem 2019;149:381–98.

[56] Iadarola MJ, Mannes AJ. The vanilloid agonist resiniferatoxin for interventional-based pain control. Curr Top Med Chem 2011;11:2171–9.

[57] Jankowski MP, Lawson JJ, McIlwrath SL, Rau KK, Anderson CE, Albers KK, Koerber HR. Sensitization of cutaneous nociceptors after nerve transection and regeneration: possible role of target-derived neurotrophic factor signaling. J Neurosci 2009;29:1636–47.

[58] Jankowski MP, Rau KK, Soneji DJ, Anderson CE, Koerber HR. Enhanced arterin/GFRAph3α levels regulate mechanically insensitive, heat-sensitive C-fiber recruitment after axotomy and regeneration. J Neurosci 2013;33:1272–83.

[59] Jarvis MF. Contributions of P2X3 homeric and heteromeric channels to acute and chronic pain. Expert Opin Ther Targets 2003;7:513–22.

[60] Jeremic A, Jefinjka K, Stevanovic J, Glavaski A, Jefinjka S. ATP induces calcium-dependent glutamate release from cultured astrocytes. J Neurochem 2001;77:664–75.

[61] Julius D. TRP channels and pain. Annu Rev Cell Dev Biol 2013;29:355–84.

[62] Kaan TK, Yip PK, Patel S, Davies M, Marchand F, Cockayne DA, Nunn PA, Dickenson AH, Ford AP, Zhong Y, Malcangio M, McMahon SB. Systemic blockade of P2X3 and P2X2/3 receptors attenuates bone cancer pain behaviour in rats. Brain 2010;133:2549–64.

[63] Kacz K, Iwemga F, Nakamura N, Nakajima M, Furukawa Y, Furukawa S. 4-Methylcatechol, an inducer of nerve growth factor synthesis, enhances peripheral nerve regeneration across nerve gaps. J Pharmacol Exp Ther 1995;272:1300–4.

[64] Kalliomaki M, Kieseritzky JV, Schmidt R, Hagglof B, Karlsten R, Sjogren J. ATP neurotrophic factor signaling. J Neurosci 2009;29:1636–47.

[65] Katz NK, Ryals JM, Wright DE. Central or peripheral delivery of an ATP inducer of nerve growth factor synthesis, protects spiral ganglion neurons in skin and other organs. Muscle Nerve 2004;29:756–67.

[66] Kang S, Wu C, Banik RK, Brennan TJ. Effect of capsaicin treatment on mechanosensitive nociceptors in rat glabrous skin one day after plantar incision. PAIN 2010;148:128–38.

[67] Kan HW, Chang CH, Lin CL, Lee YC, Hsieh ST, Hsieh YL. Downregulation of adenosine and adenosine A1 receptor contributes to neuropathic pain in resiniferatoxin neuropathy. PAIN 2018;159:1580–90.

[68] Kang S, Wu C, Banik RK, Brennan TJ. Effect of capsaicin treatment on nociceptors in rat glabrous skin one day after plantar incision. PAIN 2010;148:128–38.

[69] Katz NK, Ryals JM, Wright DE. Central or peripheral delivery of an adenosine A1 receptor agonist improves mechanical allodynia in a mouse model of painful diabetic neuropathy. Neuroscience 2015;285:312–23.

[70] Kennedy WR. Opportunities afforded by the study of unmethylated nerves in skin and other organs. Muscle Nerve 2004;29:756–67.

[71] Kennedy WR, Said G. Sensory nerves in skin: answers about painful feet?. Neurology 1999;53:1614–15.

[72] Kennedy WR, Wendelschafer-Crabb G. The innervation of human epidermis. J Neurol Sci 1993;118:94–100.

[73] Kennedy WR, Wendelschafer-Crabb G. Utility of the skin biopsy method in studies of diabetic neuropathy. Electroencephalogr Clin Neurophysiol Suppl 1999;50:553–9.

[74] Khan IM, Wennerholm M, Singletary E, Polston K, Zhang L, Deerinck T, Katz NK, Ryals JM, Wright DE. Central or peripheral delivery of an ATP inducer of nerve growth factor synthesis, protects spiral ganglion neurons in skin and other organs. Muscle Nerve 2004;29:756–67.

[75] Lin CL, Lee YC, Hsieh ST, Hsieh YL. Downregulation of adenosine and adenosine A1 receptor contributes to neuropathic pain in resiniferatoxin neuropathy. PAIN 2018;159:1580–90.

[76] Langs WR, Brennan TJ, Swain LA, Katic J, Glavaski A, Jefinjka S, Jefinjka K. ATP induces calcium-dependent glutamate release from cultured astrocytes. J Neurochem 2001;77:664–75.

[77] Lanser P, Lin YW. Endogenous adenosine regulates CFA-induced inflammatory pain by suppressing Nav1.8 through S100B, TRPV1, opioid, and adenosine pathways in mice. Sci Rep 2017;7:42531.

[78] Liao Y, Li S, Zhang JH, Pei H, Wang XG, Cheng Q. ATP induces calcium-dependent glutamate release from cultured astrocytes. J Neurochem 2001;77:664–75.

[79] Li R, Zhao C, Yao M, Song Y, Wu W, Wen A. Analgesic effect of coximarin from Radix angelicae pubescents is mediated by inflammatory factors and TRPV1 in a spared nerve injury model of neuropathic pain. J Ethnopharmacol 2017;195:81–8.

[80] Li P, Zhang Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 2017;8:460.

[81] Li S, Amici S, Tavoni H, Zeng WM, Freeland S, Fazio S, Notterpek L. PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci 2014;34:16140–52.

[82] Li P, Zhang Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 2017;8:460.

[83] Li R, Zhao C, Yao M, Song Y, Wu W, Wen A. Analgesic effect of coximarin from Radix angelicae pubescents is mediated by inflammatory factors and TRPV1 in a spared nerve injury model of neuropathic pain. J Ethnopharmacol 2017;195:81–8.

[84] Li S, Amici S, Tavoni H, Zeng WM, Freeland S, Fazio S, Notterpek L. PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci 2014;34:16140–52.

[85] Lian Y, Leandro D, Romero-Mendez C, Rodriguez-Menchaca AA, Sanchez-Armass S, Meza U. Inhibition of Cav2.3 channels by NK1 receptors is sensitive to membrane cholesterol but insensitive to caveolin-1. Pflugers Arch 2015;467:1699–709.

[86] Limbert AS, Karlo JC, Landreth GE. Nerve growth factor stimulates the activity of T-type calcium channels in dorsal root ganglion neurons. J Neurosci 2010;30:16272–83.

[87] Lim W, Hwang H, Sohn GY, Sung CT. Influence of membrane cholesterol in the molecular evolution and functional differences between neuropathy with and without pain? Exp Neurol 2011;229:199–206.

[88] Li R, Zhao C, Huang CH, Chang CH, Yi S, Cao Y, Wen X. Regulation of cell-to-cell communication in diabetic neuropathy. Kaohsiung J Med Sci 2018;34:494–502.

[89] Limpert AS, Karlo JC, Landreth GE. Nerve growth factor stimulates the activity of sodium channels in dorsal root ganglion neurons. J Neurosci 2010;30:16272–83.
[103] Mo G, Peleshok JC, Cao CQ, Ribeiro-da-Silva A, Seguela P. Control of P2X3 channel function by metabolotrop P2Y2 utp receptors in primary sensory neurons. Mol Pharmacol 2013;83:640–7.

[104] Monastyrskaya K, Hostettler A, Buergi S, Draeger A. The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity. J Biol Chem 2005;280:7135–46.

[105] Moutonova P, Allard D, Palecek J. Hypersensitivity induced by activation of spinal cord PAR2 receptors is partially mediated by TRPV1 receptors. PLoS One 2016;11:e0163991.

[106] Murrell-Lagnado RD. Regulation of P2X purinergic receptor signaling by cholesterol. Curr Top Membr 2017;80:211–32.

[107] Nakagawa T, Takashashi C, Matsuzaki H, Takeyama S, Sato S, Auzu K, Kuzuya Y, Hirohashi H. N-glycan-dependent cell-surface expression of the P2Y2 receptor and N-glycan-independent distribution to lipid rafts. Biochem Biophys Res Commun 2017;485:427–31.

[108] Nascimento D, Pozza DH, Castro-Lopes JM, Neto FL. Neuronal injury marker ATF-3 is induced in primary afferent neurons of monoaortic rats. Neurosignals 2011;19:210–21.

[109] Nies TA, Rossetti N, Reiner T, Schlittenwolf M, Moradi B. Inflammation and osteoarthritis-related pain. Schmerz 2019;33:3–34.

[110] Oaklander AL. Immunotherapy prospects for painful small-fiber sensory neuropathies and ganglionopathies. Neurotherapeutics 2016;13:108–17.

[111] Oaklander AL, Fields HL. Is reflex sympathetic dystrophy/complex regional pain syndrome type I a small-fiber neuropathy? Ann Neurol 2009;65:629–38.

[112] Obata K, Yamazaka H, Dai Y, Mizushima T, Fukukota T, Tokunaga A, Noguchi K. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur J Neurosci 2004;20:2881–9.

[113] Obreja O, Ringkamp M, Thiagu K, Bith H, Forsch E, Rukwied R, Petersen M, Schmelz M. Nerve growth factor selectively decreases activity-dependent conduction slowing in mechano-insensitive C-nociceptors. PAIN 2011;152:2138–46.

[114] Obreja O, Rukwied R, Nagler L, Schmidt M, Schmelz M, Namér B. Nerve growth factor locally sensitizes nociceptors in human skin. PAIN 2018;189:16–26.

[115] Obrosisov IC, Stavnichuk P, Drel VR, Shevaley H, Vareniuk I, Nadler JL, Schmidt RE. Different roles of 12/15-lipoxygenase in diabetic large and small fiber peripheral and autonomic neuropathies. Am J Pathol 2010;177:1436–47.

[116] Ogawa Y, Rasband MN. Proteomic analysis of optic nerve lipid rafts reveals new proteins. J Neurosci 2009;29:1586–8.

[117] Ostroff K, Namer B, Schmidt R, Schmelz M, Hilliges M, Weidner C, Carr RW, Handwerker H, Jorun E, Torebjörk H. Abnormal function of C-fibers in patients with diabetic neuropathy. J Neurosci 2006;26:11287–94.

[118] Pan HL, Khan GM, Alloway KD, Chen SR. Resiniferatoxin induces painful small-fiber sensory neuropathy. Cell Rep 2017;21:3102–15.

[119] Pang Z, Sakimoto L, Napolitano F, De Chiara V, Motta C, Studer V, Musella A, Barbieri F, Bari M, Bernardi G, Maccarrone M, Usiello A, Centonze D. Interleukin-1beta causes anxiety by interacting with the endocannabinoid system. J Neurosci 2012;32:13896–905.

[120] Paukova P, Spicarova D, Palecek J. Hypersensitivity induced by activation of spinal cord PAR2 receptors is partially mediated by TRPV1 receptors. PLoS One 2016;11:e0163991.

[121] Price TJ, Flores CM. Critical evaluation of the colocalization between calcitonin gene-related peptide, substance P, transient receptor potential subfamily type 1 immunoreactivities, and isoleucine B4 binding in primary afferent neurons of the rat and mouse. J Pain 2007;8:263–72.

[122] Puglia C, Santonocito D, Bonaccurso A, Musumeci T, Ruzzi B, Pigattelio R, Carbone C, Parenti C, Chiechio S. Lipid nanoparticle inclusion prevents capsacin-induced TRPV1 dysfunction. Pharmaceutics 2020;12:339.

[123] Rau KK, Hill CE, Harrison BJ, Venkat K, Koenig HM, Cook SB, Rabchevsky AG, Taylor BK, Hsi T, Petruska JC. Cutaneous tissue damage induces long-lasting C-fiber sensitization and regulation of cellular stress- and nerve injury-associated genes in sensory neurons. Exp Neurol 2016;283:413–27.

[124] Rosenbaum T, Simon SA, TRPV1 receptors and signal transduction. In: Liedtke WB, Heller S, editors. TRP ion channel function in sensory transduction and cellular signaling cascades. Boca Raton, FL: CRC Press/Taylor & Francis, 2007.

[125] Rossi S, Sacchetti L, Napolitano F, De Chiara V, Motta C, Studer V, Musella A, Barbieri F, Bari M, Bernardi G, Maccarrone M, Usiello A, Centonze D. Interleukin-1beta causes anxiety by interacting with the endocannabinoid system. J Neurosci 2012;32:13896–905.

[126] Ruelieh BS, Handwerker HO, Lennerz JK, Ringer R, Foster C. Brain activation during input from mechanosensitive versus polygonal C-nociceptors. J Neurosci 2006;26:5492–9.

[127] Saghy E, Payrits M, Biro-Suto T, Skoda-Foldes R, Szent-Pinter E, Erotystak J, Makkai G, Setalô G J, Korszegi T, Csepregi R, Szolcseyany J, Helyes Z, Szoke E. Carboxamid steroids inhibit the opening properties of transient receptor potential ion channels by lipid raft modulation. J Lipid Res 2018;59:1851–63.

[128] Saghy E, Szoke E, Payrits M, Helyes Z, Borzsei R, Erotystak J, Janosi T, Setalo G J, Szolcseyany J. Evidence for the role of lipid rafts and sphingomyelin in Ca-gating of Transient Receptor Potential channels in trigeminal sensory neurons and peripheral nerve terminals. Pharmacol Res 2015;100:101–16.

[129] Salinas-Ramírez MF, Vela-Bueno F, Bari M, Bernardi G, Maccarrone M, Musella A, Barbieri F, Bari M, Bernardi G, Maccarrone M, Usiello A, Centonze D. Interleukin-1beta causes anxiety by interacting with the endocannabinoid system. J Neurosci 2012;32:13896–905.

[130] Salinas-Abarca AB, Velazquez-Lagunas I, Franco-Enzastiga U, Torres-Lopez JE, Roche-Gonzalez HI, Granados-Soto V, ATF2, but not ATF3, participates in the maintenance of nerve injury-induced tactile allodynia and thermal hyperalgesia. J Pain 2018;19:174990918767627.

[131] Santello M, Bezzi P, Volterra A. TNFalpha controls glutamate transport in the hippocampal dentate gyrus. Neuron 2011;69:988–1001.

[132] Santha P, Dobos I, Kis G, Jancso G. Role of gangliosides in peripheral pain mechanisms. Int J Mol Sci 2020;21:1005.

[133] Santha P, Oszlacs O, Dux M, Dobos I, Jancso G. Inhibition of glucosylceramide synthase reversibly decreases the capsaicin-induced activation and TRPV1 expression of cultured dorsal root ganglion neurons. PAIN 2010;150:103–12.

[134] Sawynok J. Adenosine receptor targets for pain. Neuroscience 2016;338:1–18.

[135] Schmelz M, von Banchet GS, Boettger MK, Brauer R, Gaida M, Richter F, Hannele F, Brenn D, Natura G. The role of proinflammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci 2011;1290:69–90.

[136] Schmelz M, Schmid R, Handwerker HO, Torebjörk H. Encoding of burning pain from capsaicin-treated human skin in two categories of unanesthetized nerve fibers. Brain 2000;123(pt 3):560–71.

[137] Schnekenberg M, Thomas C, Schmelz M, Rukwied R. Nerve growth factor sensitizes nociceptors to C-fibre selective supra-threshold electrical stimuli in human skin. Eur J Pain 2021;25:385–97.

[138] Serra J, Collado A, Solà R, Antonelli F, Torres X, Salgueiro M, Quiles C, Bostock H. Hyperexcitable C nociceptors in fibromyalgia. Ann Neurol 2014;75:156–66.

[139] Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS. Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg 2011;112:454–9.

[140] Shi J, Jiang K, Li Z. MiR-145 ameliorates neuropathic pain via inhibiting proinflammatory cytokine production. Mol Pain 2018;14:174990918767627.

[141] Sommer C, Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol 2007;6:632–42.
[148] Sonnino S, Aureli M, Grassi S, Mauri L, Prioni S, Prinetti A. Lipid rafts in neurodegeneration and neuroprotection. Mol Neurobiol 2014;50:130–48.

[149] Sowa NA, Street SE, Vihko P, Zylka MJ. Prostatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J Neurosci 2010;30:10282–93.

[150] Szoke E, Borzsei R, Toth DM, Lengy L, Szandor Z, Szolcsanyi J. Effect of lipid raft disruption on TRPV1 receptor activation of trigeminal sensory neurons and transfected cell line. Eur J Pharmacol 2010;628:67–74.

[151] Tender GC, Li YY, Cui JG. Brain-derived neurotrophic factor redistribution in the dorsal root ganglia correlates with neuropathic pain inhibition after resiniferatoxin treatment. Spine J 2010;10:715–20.

[152] Tender GC, Li YY, Cui JG. The role of nerve growth factor in neuropathic pain inhibition produced by resiniferatoxin treatment in the dorsal root ganglia. Neurosurgery 2013;73:158–65; discussion 165-156.

[153] Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Bastbaum AI, Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998;21:531–43.

[154] Vaccar F, Amadio S, Sancesario G, Bernardi G, Volonte C. P2X3 receptor localizes into lipid rafts in neuronal cells. J Neurosci Res 2004;76:653–61.

[155] Wallace M, Pappagallo M. Qutenza(R): a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev Neurother 2011;11:15–27.

[156] Wang H, Jiang M, Cui H, Chen M, Buttyan R, Hayward SW, Hai T, Wang Z, Yan C. The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor. Mol Cell Biol 2012;32:3190–202.

[157] Wang S, Kim M, Ali Z, Ong K, Pae EK, Chung MK. TRPV1 and TRPV1-expressing nociceptors mediate orofacial pain behaviors in a mouse model of orthodontic tooth movement. Front Physiol 2019;10:1207.

[158] Watson G, Ronai ZA, Lau E. ATF2, a paradigm of the multifaceted regulation of transcription factors in biology and disease. Pharmacol Res 2017;119:347–57.

[159] Wheeler MA, Heffner DL, Kim S, Espy SM, Spano AJ, Cleland CL, Deppmann CD. TNF-alpha/TNFR1 signaling is required for the development and function of primary nociceptors. Neuron 2014;82:587–602.

[160] Wildgaard K, Ringsted TK, Hansen HJ, Petersen RH, Werner MU, Kehlet H. Quantitative sensory testing of persistent pain after video-assisted thoracic surgery lobectomy. Br J Anaesth 2012;108:126–33.

[161] Wright DE, Ryals JM, McCarson KE, Christianson JA. Diabetes-induced expression of activating transcription factor 3 in mouse primary sensory neurons. J Peripher Nerv Syst 2004;9:242–54.

[162] Wu CH, Ho WY, Lee YC, Lin CL, Hsieh YL. EXPRESS: NGF-trkA signaling modulates the analgesic effects of prostatic acid phosphatase in resiniferatoxin-induced neuropathy. Mol Pain 2016;12:1744806916656846. doi: 10.1177/1744806916656846.

[163] Zhang L, Berta T, Xu ZZ, Liu T, Park JY, Ji RR. TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. PAIN 2011;152:419–27.

[164] Zylka MJ. Pain-relieving prospects for adenosine receptors and ectrornucleotidases. Trends Mol Med 2011;17:188–96.